Guardant Health, Inc. GH R2KR3KPHARMA
Company Overview
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Why Investors Should Care
Revenue has grown at a 50.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $982.02M (+32.9% YoY); net profit $-416.28M.
- Trailing 12 Months Year-on-year growth — revenue +44.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 50.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 50.19% |
| 1 Year: | 44.30% |
Stock Price Performance
| 1 Year: | +175.58% |
| 6 Months: | +76.98% |
| 3 Months: | +28.50% |
| 1 Month: | +2.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.21 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 50.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GH Guardant Health, Inc. R2KR3KPHARMA | 161.41 | -45.99 | $21.66B | 0.00% | -25.56% | - | 50.19% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 168.49M | 177.24M | 191.48M | 203.47M | 232.09M | 265.20M | 301.67M | 334.98M |
| Operating Income | -28.68M | -18.65M | -22.70M | -24.20M | -23.66M | -15.27M | -17.48M | -34.91M | -54.62M | -74.25M | -107.86M | -97.64M | -107.29M | -123.34M | -130.32M | -144.60M | -134.06M | -119.62M | -113.54M | -99.68M | -100.62M | -117.33M | -111.04M | -106.41M | -98.99M | -121.35M | -129.12M |
| Net Income | -28.59M | - | - | -24.46M | - | - | - | - | - | - | - | - | - | -123.23M | -229.43M | -161.99M | -133.53M | -72.77M | -86.10M | -114.98M | -102.63M | -107.75M | -95.16M | -99.90M | -92.72M | -112.08M | -120.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.57 | -0.78 | -1.09 | -0.96 | -1.06 | -1.21 | -2.25 | -1.58 | -1.30 | -0.67 | -0.73 | -0.94 | -0.84 | -0.88 | -0.77 | -0.80 | -0.74 | -0.85 | -0.90 |
| R&D Expense | 7.25M | 8.26M | 11.55M | 14.25M | 16.32M | 19.53M | 24.57M | 37.02M | 36.32M | 36.24M | 55.51M | 63.72M | 70.97M | 81.76M | 85.45M | 100.02M | 93.13M | 90.36M | 93.85M | 83.80M | 83.10M | 87.31M | 88.52M | 87.45M | 89.96M | 91.04M | 96.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.25M | 49.84M | 90.64M | 214.38M | 286.73M | 373.65M | 449.54M | 563.95M | 739.02M | 982.02M |
| Operating Income | -43.85M | -76.61M | -92.94M | -82.37M | -254.95M | -411.00M | -544.38M | -564.73M | -443.59M | -437.25M |
| Net Income | -46.14M | -83.22M | -85.06M | -75.65M | -253.78M | -384.77M | -654.59M | -479.45M | -436.37M | -416.28M |
| Diluted EPS | - | - | - | -0.84 | -2.60 | -4.00 | -6.41 | -4.28 | -3.56 | -3.32 |
| R&D Expense | 10.86M | 25.56M | 50.71M | 86.29M | 149.86M | 263.22M | 373.81M | 367.19M | 347.75M | 364.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 342.94M | 587.40M | 962.53M | 2.27B | 2.20B | 1.61B | 1.79B | 1.49B | 2.01B |
| Total Equity | 83.44M | 79.70M | 308.61M | 483.15M | 798.39M | 1.30B | 645.00M | 60.18M | 158.68M | -139.65M | -99.31M |
| Cash & Equivalents | - | - | 72.28M | 140.54M | 143.23M | 832.98M | 492.20M | 141.65M | 1.13B | 525.54M | 378.20M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 1.14B | 1.50B |
| Total Liabilities | - | - | 34.33M | 62.45M | 114.54M | 916.19M | 1.56B | 1.55B | 1.63B | 1.63B | 2.11B |
| Current Liabilities | - | - | 19.63M | 46.94M | 72.73M | 66.81M | 194.69M | 193.22M | 205.92M | 225.58M | 302.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.71M | -72.23M | -72.19M | -47.13M | -103.93M | -209.02M | -309.46M | -324.98M | -239.86M | -184.76M |
| Investing Cash Flow | 26.20M | -170.42M | -153.03M | -317.57M | -617.09M | -63.16M | 149.82M | 840.25M | -261.31M | -627.20M |
| Financing Cash Flow | 39.84M | 281.66M | 293.16M | 367.30M | 1.41B | -66.82M | -189.09M | 477.38M | -996.00K | 671.13M |
| Capital Expenditure | -1.77M | -6.68M | -20.20M | -18.72M | -36.17M | -75.03M | -77.46M | -20.49M | -35.09M | -48.31M |
| Free Cash Flow | -38.48M | -78.92M | -92.39M | -65.85M | -140.10M | -284.05M | -386.92M | -345.46M | -274.94M | -233.07M |
| Share Buybacks | 100.00K | 7.22M | 172.00K | 0 | 0 | - | - | 0 | 0 | 45.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -173.7% | -153.7% | -102.5% | -38.4% | -88.9% | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% |
| Net Margin % | -182.7% | -167.0% | -93.8% | -35.3% | -88.5% | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% |
| ROE % | -57.9% | -27.0% | -17.6% | -9.5% | -19.5% | -59.7% | -1,087.7% | -302.1% | 312.5% | 419.2% |
| ROCE % | - | -23.7% | -17.2% | -9.3% | -11.6% | -20.4% | -38.4% | -35.7% | -35.2% | -25.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.68% | 7.62M | $1.23B |
| 2 | Price (T.Rowe) Associates Inc | 4.85% | 6.51M | $1.05B |
| 3 | Vanguard Capital Management LLC | 4.29% | 5.76M | $929.57M |
| 4 | FMR, LLC | 4.09% | 5.49M | $886.36M |
| 5 | Vanguard Portfolio Management LLC | 4.06% | 5.45M | $879.49M |
| 6 | Invesco Ltd. | 3.30% | 4.43M | $715.41M |
| 7 | Goldman Sachs Group Inc | 2.81% | 3.78M | $609.81M |
| 8 | Two Sigma Investments, LP | 2.77% | 3.72M | $600.67M |
| 9 | Capital International Investors | 2.53% | 3.40M | $549.04M |
| 10 | Deep Track Capital, Lp | 2.53% | 3.39M | $548.02M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GH
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE04UlZuVGRFeW5XZEFtVnVoalNIQW5kQzhITTJ3RmVNRXQ5T3F0QmxPcFBDbUJKS2lDRk5YT1JCRk16WVZmZnRibWxTOVA5QQ?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <font …
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9BRFpDSng0VTNKOFJwVVZoNFg0YjJUNk5WUkVRdWEwQk1yRUxqdUp6Q1EtYTdXWVhDb1ptc05GcnFUMWlZemc?oc=5" target="_blank">Guardant Health Stock Price Forecast. Should You Buy GH?</a> …
Guardant Health (GH) Stock Could Trade At A 21% Discount Despite Patent Appeal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOSFByaFBFMklueEVzck5YeFZoNVJzcW1JQ1FYcDgzMEVnNkZUZGN0TlVVR3o4R25JbUNnWWhnY003NVFjdjA1SWQ4bDhQaFp3djdpR2h4M3kzUHl4Wjd0TndfZ0lpX25PR2VxOXlsRWhiX0p0LU8zRXNHcjY5Mll2cC0tN3NUbWw3Z0ZXTm…
IBD Stock Of The Day Spikes After Hiking 2026 Revenue Outlook - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOZkdMTUgxNUhWd3lVZzR5ZHFIU0YzRnA4eGNKZUFmS0U1VF9jVWVCMEdXVXdaV3htNGE2Y2ozdkRxZmkzN1NxU3ZIc042NUpzRDJQRlN3QkhHZEtnTXYyemliUDJhYndwc09ITkJPemhTYWRvWHJQbjRHU2tlWUZCWW42SVcwdGhDTTdKay…
Guardant Health Stock Surges 19%, With A 5-Day Winning Spree - Trefis
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVjMwa29pZlVNUFZPalNMOXhIZnRtODlvNkZwUERCTXNPN3lNcW85Mk1MVGJobHlKMi1KVDdrelZ4U0lPa3NGb1hmZTB4NWtIT0h5QjNqbU1YNDQ2SzVSMk4xRWlSbnVuVGQ5VDdNUHBCZXFHNXRlZlYwaG91MWJNT0FXc1BCOGl3REtTd1…
Guardant Health: An Expensive Price For A Great Company - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQclk2bGpLeDkySWNMMmpBeGxTZ1RObHZuckJmWHAyYktRRWszbmlNTWhoWVlsMjh5NVFsOUg3N0k5SUIzc0wzdV9NNHIzblk0a1hpa2FhT1oyMGIteGxMT3JyMnNleWx5d3VaMUVnZHhPQ2s1QzM2bFZWOUxrOUFLQjJjWUwwdXBWWC1UYz…
GH — Frequently Asked Questions
What is the current share price of Guardant Health, Inc. (GH)?
As of 2026-09-07 16:24 PDT, Guardant Health, Inc. (GH) trades at $161.41 on NasdaqGS. Its 52-week range is $54.79 to $170.92.
What is the market capitalisation of GH?
Guardant Health, Inc. (GH) has a market capitalisation of $21.66B on NasdaqGS.
What is the P/E ratio of GH?
GH trades at a trailing price-to-earnings (P/E) ratio of -45.99. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -101.01.
Is GH a good stock to buy?
This page provides a data-driven analysis of Guardant Health, Inc. (GH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.